Background: Globally, people are impacted by the heterogeneous and multifactorial condition known as stroke. The breakdown of the blood-brain barrier (BBB), the development of edoema, the activation of proinflammatory cytokines, and the loss of myelin proteins are all pathogenic events connected to ischemic stroke that are mediated by metalloproteinase-9. In acute ischemic stroke patients, the high level of matrix metalloproteinase-9 is closely linked to infarct extension, neurological impairments, and hemorrhagic transformation.